Nasdaq:US$9.61 (+0.03) | HKEX:HK$15.54 (-0.82) | AIM:£1.57 (+0.01)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors